General discussion, page-1111

Yes but that was in a raging pot bull market. Even the dogs were lifted up in that one albeit IHL was the best performer and retained its performance even across the crazy year that was 2020.

But the way we are trading makes me think we are starting to be considered as Ted said a BIOTECH first and foremost with the oils sales underpinning. IMO when the quarterly comes out and they forecast huge growth in Q3 -> future sales AND if my theory is correct and we are indeed practically replacing Althea Group as Cannvalate will favor us when prescribing, then we should surely be worth closer to 100M based on the underlying oils business.

On IP though, depends how the market views it. I am on the conservative side here but still think it will explode when we get Stage 2 findings, FDA pathway rego and plans to commence a human trial for ARDS. Either way I can see this easily pushing into the teens off the back of that ann, for this ann I want to say 8-9c but I could be wrong and the market may LOVE it.